Fig. 1: Trial profile.
From: First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Diagram indicating participant numbers and disposition through the course of the trial. QD, once daily.
Fig. 1: Trial profile. | Nature Communications
